Literature DB >> 28353129

Management of Hepatoblastoma: ICMR Consensus Document.

Sandeep Agarwala1, Alisha Gupta2, Deepak Bansal3, Tushar Vora4, Maya Prasad4, Brijesh Arora4, Gauri Kapoor5, Girish Chinnaswamy4, Venkatraman Radhakrishnan6, Siddharth Laskar7, Tanvir Kaur8, Rupinder Singh Dhaliwal8, G K Rath9, Sameer Bakhshi10.   

Abstract

Dramatic advancement has been made in the management of children with hepatoblastoma (HB) over the past 3 decades owing to the improvement in diagnostic imaging, new chemotherapeutic agents, better surgical care and availability of liver transplantation. These advances are the end results of contributions from 4 major study groups across the globe including International Society of Pediatric Oncology - Liver Tumor Strategy Group (SIOPEL), Children's Oncology Group (COG), German Pediatric Hematology Oncology Group (GPOH) and Japanese Pediatric Liver Tumor Study Group (JPLT). The current manuscript is written with the objective of developing a consensus guideline for practitioners at a National level. Based on literature and personal experience over last 3 decades, the Indian Council of Medical Research (ICMR) Expert group has made recommendations for management of children with HB in resource-challenged nations including India.

Entities:  

Keywords:  Diagnosis; Hepatoblastoma; Indian context; Treatment

Mesh：

Year:  2017        PMID： 28353129     DOI： 10.1007/s12098-017-2301-9

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  30 in total

1.  [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver ].

Authors:  C COUINAUD
Journal:  Presse Med       Date:  1954-05-05       Impact factor: 1.228

2.  Hepatoblastoma: experience from a single center.

Authors:  T Singh; C T Satheesh; L Appaji; B S Aruna Kumari; M Padma; M V Kumar; G Mukherjee
Journal:  Indian J Cancer       Date:  2010 Jul-Sep       Impact factor: 1.224

3.  Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.

Authors:  J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

4.  Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.

Authors:  József Zsíros; Rudolf Maibach; Elizabeth Shafford; Laurence Brugieres; Penelope Brock; Piotr Czauderna; Derek Roebuck; Margaret Childs; Arthur Zimmermann; Veronique Laithier; Jean-Bernard Otte; Beatriz de Camargo; Gordon MacKinlay; Marcelo Scopinaro; Daniel Aronson; Jack Plaschkes; Giorgio Perilongo
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

5.  Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology.

Authors:  J Pritchard; J Brown; E Shafford; G Perilongo; P Brock; C Dicks-Mireaux; J Keeling; A Phillips; A Vos; J Plaschkes
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

6.  Marked response to preoperative high-dose cis-platinum in children with unresectable hepatoblastoma.

Authors:  C T Black; A Cangir; M Choroszy; R J Andrassy
Journal:  J Pediatr Surg       Date:  1991-09       Impact factor: 2.545

7.  Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.

Authors:  Giorgio Perilongo; Rudolf Maibach; Elisabeth Shafford; Laurence Brugieres; Penelope Brock; Bruce Morland; Beatriz de Camargo; Jozsef Zsiros; Derek Roebuck; Arthur Zimmermann; Daniel Aronson; Margaret Childs; Eva Widing; Veronique Laithier; Jack Plaschkes; Jon Pritchard; Marcello Scopinaro; Gordon MacKinlay; Piotr Czauderna
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

8.  Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).

Authors:  József Zsíros; Laurence Brugières; Penelope Brock; Derek Roebuck; Rudolf Maibach; Margaret Child; Bruce Morland; Michela Casanova; Daniele Pariente; Claudia Paris; Beatriz de Camargo; Milind Ronghe; Arthur Zimmermann; Jack Plaschkes; Piotr Czauderna; Giorgio Perilongo
Journal:  Eur J Cancer       Date:  2012-07-24       Impact factor: 9.162

9.  Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.

Authors:  Howard M Katzenstein; Kay W Chang; Mark Krailo; Zhengjia Chen; Milton J Finegold; Jon Rowland; Marleta Reynolds; Alberto Pappo; Wendy B London; Marcio Malogolowkin
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

10.  Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma.

Authors:  Rebecka L Meyers; Howard M Katzenstein; Mark Krailo; Eugene D McGahren; Marcio H Malogolowkin
Journal:  J Pediatr Surg       Date:  2007-12       Impact factor: 2.545
View more
  10 in total

1.  Editorial: Indian Guidelines for Treatment of Pediatric Malignancies.

Authors:  Akash Tiwari; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2017-03-16       Impact factor: 1.967

2.  Treatment optimization for recurrent hepatoblastoma: retrospective study from a hepatoblastoma cohort in Southern China.

Authors:  Yuanqi Wang; Huadong Chen; Yixuan Liu; Han Xiao; Xiaoshuai Wang; Zhihai Zhong; Pengfei Gao; Zhichong Zhang; Jinbiao She; Juncheng Liu; Leilei Huang; Hong Jiang
Journal:  Pediatr Surg Int       Date:  2022-04-18       Impact factor: 1.827

3.  Comparison of Cisplatin Monotherapy and PLADO in the Management in Children with Standard-Risk Hepatoblastoma in a Resource-Challenged Nation.

Authors:  Sandeep Agarwala; Vishesh Jain; Anjan Dhua; Madur Srinivas; Prabudh Goel; Sameer Bakhshi; Venkateswaran K Iyer; Rajni Yadav; Manisha Jana; Priyanka Naranje; Veereshwar Bhatnagar
Journal:  J Indian Assoc Pediatr Surg       Date:  2022-05-12

Review 4.  'Teratoid' Hepatoblastoma: An Intriguing Variant of Mixed Epithelial-Mesenchymal Hepatoblastoma.

Authors:  Consolato M Sergi; Marta Rojas-Vasquez; Michelle Noga; Bryan Dicken
Journal:  Children (Basel)       Date:  2022-04-15

5.  Upper Transversal Hepatectomy for Pediatric Liver Tumors Based on the Inferior Right Hepatic Vein.

Authors:  Mufaddal Khuzema Kazi; Sajid Shafique Qureshi
Journal:  J Indian Assoc Pediatr Surg       Date:  2021-11-12

6.  Clinical Profile of Hepatoblastoma: Experience From a Tertiary Care Centre in a Resource-Limited Setting.

Authors:  Arkadeep Dhali; Tuhin S Mandal; Somak Das; Gautam Ray; Prasenjit Halder; Debarshi Bose; Suparna K Pal; Sukanta Ray; Abhijit Chowdhury; Gopal Krishna Dhali
Journal:  Cureus       Date:  2022-07-01

7.  Outcomes for high-risk hepatoblastoma in a resource-challenged setting.

Authors:  A Rammohan; M Rela; G V Kumar; J X Scott; N Shanmugam; M S Reddy; P Ramachandran
Journal:  BJS Open       Date:  2020-05-07

Review 8.  Advances in the Surgical Treatment of Neuroblastoma.

Authors:  Yan-Bing Luo; Xi-Chun Cui; Lin Yang; Da Zhang; Jia-Xiang Wang
Journal:  Chin Med J (Engl)       Date:  2018-10-05       Impact factor: 2.628

9.  Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles.

Authors:  Xiao-Dong Wang; Jin-Bo Peng; Chuan-Yang Zhou; Qiao Que; Hai-Yuan Li; Yun He; Hong Yang
Journal:  Oncol Rep       Date:  2020-03-16       Impact factor: 3.906

10.  Clinical and Pathological Study of Tumor Border Invasion-Is Narrow Resection Margin Acceptable in Hepatoblastoma Surgery?

Authors:  Gang Shen; Linlin Wu; Jie Zhao; Bin Wei; Xianjun Zhou; Feifei Wang; Jie Liu; Qian Dong
Journal:  Front Med (Lausanne)       Date:  2020-03-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.